ASLN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients...

Stats
Today's Volume	1.49M
Average Volume	1.18M
Market Cap	9.29M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.680 ) 2024-04-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.170
ATR14	$0.0110 (2.35%)

Volume Correlation

Long: -0.30 (neutral)

Short: -0.18 (neutral)

Signal:(46.535) Neutral

ASLAN Pharmaceuticals Correlation

10 Most Positive Correlations
TYRA	0.946
RCEL	0.946
SHIP	0.943
ASUR	0.943
XLRN	0.942
OPRA	0.94
AMPH	0.939
RDNT	0.934
FLMN	0.934
LFMDP	0.933

10 Most Negative Correlations
GOODN	-0.944
WISH	-0.943
TBIO	-0.935
TREE	-0.934
UPLD	-0.931
MICS	-0.929
GMVD	-0.927
AVGR	-0.925
BAND	-0.925
GOODO	-0.924

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ASLAN Pharmaceuticals Correlation - Currency/Commodity

0.06
( neutral )

-0.37
( neutral )

0.00
( neutral )

0.51
( weak )

ASLAN Pharmaceuticals Financials

Annual	2022
Revenue:	$0
Gross Profit:	$-331 752 (0.00 %)
EPS:	$-3.68

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.560

Q2	2023
Revenue:	$12.00M
Gross Profit:	$12.00M (100.00 %)
EPS:	$-0.110

Q2	2023
Revenue:	$12.00M
Gross Profit:	$12.00M (100.00 %)
EPS:	$-0.110

Financial Reports:

No articles found.

ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Realtime updates for ASLAN Pharmaceuticals [ASLN]

Upcoming Earnings Alert